Compare · MAZE vs MRNA
MAZE vs MRNA
Side-by-side comparison of Maze Therapeutics Inc. (MAZE) and Moderna Inc. (MRNA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MAZE and MRNA operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- MRNA is the larger of the two at $80.65B, about 45.5x MAZE ($1.77B).
- MRNA has been more active in the news (16 items in the past 4 weeks vs 7 for MAZE).
- MRNA has more recent analyst coverage (25 ratings vs 9 for MAZE).
- Company
- Maze Therapeutics Inc.
- Moderna Inc.
- Price
- -
- -
- Market cap
- $1.77B
- $80.65B
- 1M return
- -
- -18.99%
- 1Y return
- -
- +791.08%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2025
- 2018
- News (4w)
- 7
- 16
- Recent ratings
- 9
- 25
Moderna Inc.
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, and Bill & Melinda Gates Foundation. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of COVID-19 vaccine; and Catalent Inc., Laboratorios Farmacéuticos Rovi, S.A., Recipharm, and Lonza Group for fill-finish manufacturing of its COVID-19 vaccine candidate, as well as Aldevron, LLC for supporting COVID-19 vaccine and additional programs in company's clinical development pipeline. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Latest MAZE
- SEC Form 10-Q filed by Maze Therapeutics Inc.
- Maze Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Maze Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights
- Chief Executive Officer Coloma Jason V sold $1,043,766 worth of shares (34,501 units at $30.25) as part of a pre-agreed trading plan (SEC Form 4)
- Maze Therapeutics to Participate in Upcoming Investor Conferences
- SEC Form 144 filed by Maze Therapeutics Inc.
- CSBO Dandekar Atul sold $240,532 worth of shares (7,500 units at $32.07) as part of a pre-agreed trading plan (SEC Form 4)
- Canaccord Genuity initiated coverage on Maze Therapeutics with a new price target
- SEC Form 8-K filed by Maze Therapeutics Inc.
- Maze Therapeutics to Present Data from MZE829 and MZE782 Programs at ASN Kidney Week 2026
Latest MRNA
- President Stephen Hoge exercised 152,905 shares at a strike of $12.21, sold $16,900,019 worth of shares (78,375 units at $215.63) as part of a pre-agreed trading plan and gifted 400,000 shares, decreasing direct ownership by 20% to 1,311,095 units (SEC Form 4)
- Moderna Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits
- Moderna Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Moderna Outlines Next Phase of Growth at Analyst Day
- Moderna Announces JAMA Network Open Publication of Real-World Comparative Effectiveness Data for mNEXSPIKE (COVID-19 Vaccine, mRNA) in Adults Aged 65 Years and Older
- Moderna to Present at Upcoming Conference in November 2026
- Chief Operating Officer Andres Juan was granted 7,898 stock options and was granted 16,955 restricted stock units (SEC Form 4)
- SEC Form 10-Q filed by Moderna Inc.
- Moderna Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Moderna Reports Third Quarter 2026 Financial Results and Provides Business Updates